1.Evaluation of computed tomography of post embolized hepatic tumors
Hyung Sik YOO ; Jong Tae LEE ; Jung Ho SUH ; Heun Y. YUNE
Journal of the Korean Radiological Society 1986;22(6):984-990
We have evaluated the post-embolization findings of hepatic tumors(15 cases of hepatoma, and 5 cases ofmetastatic tumors)using Ivalon particles in conjunction with the pre-embolization status of CT. Serial CTexaminations were done every 3 week intervals after embolization procedure. Findings were as follows: 1. Inhepatoma, tumor volume was decreased in 7 cases at 3 week after procedure. Among which 5 cases revealed tumorvolume decrease of 0 to 25 percent. 2. Most important findings of post embolized hepatic tumors was decreasedtumoral density and attenuation of tumor wall enhancement. 3. Intratumoral air was developed within 3 week afterembolization and appeared as mottled or linear branching patterns in the center or periphery of the tumor. 4. Itseems to be important to observe the change of intratumoral density and measurement of tumoral volume to determinethe reembolizatin procedure.
Carcinoma, Hepatocellular
;
Tumor Burden
2.The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden.
Journal of Gynecologic Oncology 2011;22(4):299-300
No abstract available.
Humans
;
Ovarian Neoplasms
;
Tumor Burden
3.The Effect of Gamma Knife Surgery on Uveal Melanoma.
Jae Young CHOI ; Kyung Hoe LEE ; Yong Gu PARK ; Sang Sup CHUNG
Journal of Korean Neurosurgical Society 1997;26(9):1228-1230
The optimal management of uveal melanoma is still a matter of controversy. To determine the effect of Gamma Knife surgery on patients with uveal melanoma, the authors reviewed the outcome of five operations performed between September 1993 and August 1996. The mean age of the patients was 60.7(range 42 to 76) years; the median follow-up period was 10 months, and four patients were followed up for more than 6 months. The mean tumor volume was 3442mm3(mean diameter 15.3mm) and all patients were irradiated with a mean maximum dose of 74Gy (range 60-80Gy), using a 50% isodose on the tumor margin. In one patient, the tumor disappeared completely 32 months after Gamma Knife surgery; because the tumor did not regress, one patient subsequently required enucleation, and two remained stable. During a mean follow-up period of 10 months, vision was preserved in two patients, but one went blind; in one, enucleation was performed because the tumor did not regress. These results suggest that in cases of uveal melanoma Gamma Knife surgery can effectively control local tumors, can spare the eyeball, and may prevent loss of vision.
Follow-Up Studies
;
Humans
;
Melanoma*
;
Tumor Burden
4.The Comparison of DVH between Multiple arc FSRT and Conformal FSRT.
Ki Hwan KIM ; Jun Sang KIM ; Ji Young JANG ; Jae Sung KIM ; Seong Ho KIM ; Chang Joon SONG ; Min Kyu PARK ; Moon June CHO
The Journal of the Korean Society for Therapeutic Radiology and Oncology 1999;17(3):261-267
PURPOSE: .In FSRT (Fractionated stereotactic radiotherapy) planning, we studied the usefulness between multiple arc FSRT and conformal FSRT by comparing tumor shape and DVH(dose volume histogram). MATERIALS AND METHDS: In Chungnam Univ. hospital, we had treated the sixteen patients with FSRT from Aug. 1997 to Dec. 1998. In choosing multiple arc FSRT or conformal FSRT, we had considered multiple arc FSRT if tumor shape was similar to sphere or the value of IF was less than 1.25, conformal FSRT if tumor shape was very irregular or IF was more than 1.3. For evaluation of treatment planning, we had considered the appropriate DVH for tumor volume and for critical organs. RESULT: The errors between reference point and the coordinates point on AP, Lat radiography were less than 1 mm before treatment. We had planned 3~5 arcs for multiple arc FSRT, 5~6pots for conformal FSRT. The mean dose distribution of tumor volume of cumulative DVH between multiple arc FSRT and conformal FSRT was 90.6, 86%, respectively. The dose of critical organs irradiated was less than 5% maximum dose of cumulative DVH. CONCLUSION: We had obtained the similar value between multiple arc FSRT and conformal FSRT, so that we had appropriate treatment planning of FSRT for multiple arc FSRT and conformal FSRT according to tumor shape and size.
Chungcheongnam-do
;
Humans
;
Radiography
;
Tumor Burden
5.High Stage Prostate Cancer with Low Serum PSA Level: A Case Report.
Sei Kyung RHO ; Duk Kyo KIM ; Sang Cheol LEE ; Sung Goo CHANG ; Jin Il KIM
Korean Journal of Urology 1996;37(8):947-950
Serum prostatic specific antigen (PSA) will be elevated in cases of BPH, prostatitis, prostatic cancer, and other conditions of prostate. Generally PSA is proportional to increased the size of the transitional zone of the prostate, but the PSA production by malignant glands is variable PSA production is depend on the degree of histologic differentiation in case of prostate cancer, with well-differentiated glands producing more PSA and undifferentiated cancer producing less PSA. Significant elevations of PSA, greater than 10 to 20 ng/ml, in the absence of prostatitis, or recent prostatic biopsy are strongly suggestive of cancer of the prostate. Several large scale studies have demonstrated that serum PSA correlates well with advancing clinical stage, tumor volume and pathological stage. We report a case in which high stage and poorly differentiated pathologic grade prostate cancer with low serum PSA level.
Biopsy
;
Prostate*
;
Prostatic Neoplasms*
;
Prostatitis
;
Tumor Burden
6.Novel biological strategies to enhance the radiation therapeutic ratio
Jae Ho KIM ; Kenneth A JENROW ; Stephen L BROWN
Radiation Oncology Journal 2018;36(3):172-181
Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration. To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio.
Aging
;
Radiobiology
;
Radioimmunotherapy
;
Signal Transduction
;
Tumor Burden
7.A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma.
Young Jin YUH ; Hyun Su KIM ; Young Jung PARK ; Heung Sik UM ; Sang Bong CHOI ; Ban Suck LEE ; Sung Rok KIM ; Tae Hui HAN
Korean Journal of Hematology 2005;40(3):188-191
Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
Humans
;
Multiple Myeloma*
;
Plasmacytoma
;
Thalidomide*
;
Tumor Burden
8.Comparison of Gallium - 68 Prostate-Specific Membrane Antigen (Ga-68 PSMA) normal tissue uptake across tumor burden groups among Filipino patients with prostate cancer
Mary Stephanie Jo C. Estrada ; Eduardo Erasto S. Ongkeko ; Mia Anne Ryna L. Bayot ; Kalvin B. Catubao ; Klein Reagan R. Bautista ; Patricia A. Bautista - Penalosa
The Philippine Journal of Nuclear Medicine 2021;16(2):26-36
Background:
PSMA-targeted radiopharmaceuticals have been widely studied for their theragnostic role in prostate cancer
and were introduced in the Philippines in 2018. The optimal administered activity of 177Lu-PSMA for targeted
endoradiotherapy has not yet been established and is thought to be influenced by several factors, including
tumor burden. This study investigates the effect of tumor burden on the normal tissue PSMA uptake among
Filipino patients with prostate cancer using its diagnostic counterpart, 68Ga-PSMA I&T
Methods:
One hundred four patients imaged with 68Ga-PSMA I&T PET/CT in our institution from January 2018 to May
2020 were included. Patients were visually classified into low, medium, and high tumor burden groups.
Maximum and mean standardized uptake values (SUVmax and SUVmean) of the lacrimal glands, parotid
glands, submandibular glands, kidneys, liver, spleen, and bone were measured and compared among tumor
burden groups.
Results and Conclusions
68Ga-PSMA I&T uptake in the kidneys, the salivary glands, and the liver, were significantly reduced by
approximately 25-50% in patients with high tumor burden. This finding supports the hypothesis that patients
with higher tumor load can tolerate higher activity doses of 177Lu-PSMA for endoradiotherapy before developing
significant damage to the critical organs. This may serve as a guide towards optimizing and personalizing
177Lu-PSMA I&T administered activity dose for radionuclide therapy
Positron-Emission Tomography
;
Prostatic Neoplasms
;
Tumor Burden
9.Effect of Intraarterial and Systemic Chemotherapy for Stage IIb Cervical Carcinoma: Assessment of TherapeuticResponse Using MR Imaging.
Ji Young YOO ; Kie Hwan KIM ; Jeong Eun SOHN ; Dong Hee PARK ; Soo Yil CHIN
Journal of the Korean Radiological Society 1998;39(5):971-976
PURPOSE: To evaluate the effectiveness of intraarterial chemotherapy(IAC) and systemic chemotherapy(SC) incases of locally advanced cervical carcinoma, and to assess the accuracy of magnetic resonance(MR) imaging fordetermining parametrial invasion after IAC or SC. MATERIALS AND METHODS: Among 44 patients with stage IIbcervical carcinoma, IAC was performed in 25 and SC in 19. MR images obtained before and after IAC or SC wereprospectively analyzed with regard to tumor volume and parametrial invasion, and tumor response to chemotherapywas classified as complete, partial, or progressive. Forty-one patients underwent radical hysterectomy within twoweeks of the second MR examination, and postoperative pathologic findings were correlated with radiologicfindings. RESULTS: The average reduction rate of tumor volume in the IAC and SC group was 89.2% and 66.3%,respectively. Between the two groups, there was no statistically significant difference(P>0.05). In the IAC group,13 patients showed a complete response and 11 a partial response, and in one there was progression. In the SCgroup, eight patients showed a complete response and nine a partial response, and in two there was progression.The accuracy of MR imaging for determining parametrial invasion after chemotherapy was 87.8%. In each patientthere was close correlation between MR imaging and pathologic findings. CONCLUSION: There was no statisticallysignificant difference in tumor reduction between the IAC and SC group. After chemotherapy for stage IIb cervicalcarcinoma, MR imaging is a valuable modality for determining surgical candidates.
Drug Therapy*
;
Humans
;
Hysterectomy
;
Magnetic Resonance Imaging*
;
Tumor Burden
10.The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer.
Annals of Coloproctology 2013;29(2):44-54
There are still debates regarding the appropriate primary treatment policy for asymptomatic primary colorectal lesions in cases of unresectable metastatic colorectal cancer. Even though there are patients with asymptomatic primary tumors when starting chemotherapy, those patients may still undergo surgery due to complications related to primary tumors in the middle of chemotherapy; therefore, controversy exists regarding surgical resection of primary colorectal lesions in cases where symptoms are absent when making a diagnosis. Thus, based on the published literature, we discuss opinions that prefer first-line surgery for primary tumors as well as opinions favoring first-line chemotherapy for treating unresectable synchronous metastatic colorectal cancer. Although the upfront chemotherapy including targeted agents is suggested as an effective treatment in recent years, the first line surgery has been a preferred treatment for decades. The first line surgery is beneficial to prolong the survival duration given the retrospective analysis of randomized trial data. So far, no prospective comparison study has only focused on the first-line treatment modality; thus, future clinical studies focusing on the survival duration and the quality of life should be performed as soon as possible. Furthermore, at this point, multidisciplinary team approaches would be helpful in finding the appropriate therapy. Regardless of symptoms, the performance status and the tumor burden should be taken into consideration as well. In case of surgical resection, minimally invasive surgery, such as laparoscopic surgery, is recommended.
Colorectal Neoplasms
;
Humans
;
Laparoscopy
;
Quality of Life
;
Tumor Burden